Salute e Benessere

Telix Submits NDA for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent

There is a critical unmet need to improve the diagnosis and management of glioma, particularly in the post-treatment setting. With low survival rates and the need to make rapid decisions, precision imaging is paramount. Subject to regulatory approval, Pixclara®1 has the potential to address this need, enabling patients to receive greater clarity in their diagnosis and treatment decision making. Pixclara®1 is also being developed as the "companion" theranostic imaging agent for TLX101…
PR Newswire
28/08/2024

Global Heart Closure Devices Market to Witness Upsurge in Growth at a CAGR of…

Key Takeaways from the Heart Closure Devices Market Report Key Takeaways from the Heart Closure Devices Market Report To read more about the latest highlights related to the heart closure devices market, get a snapshot of the key highlights entailed in the Global Heart Closure Devices Market Report Heart Closure Devices Overview Heart closure devices are medical tools designed to treat structural defects in the heart, such as atrial septal defects (ASD), patent foramen ovale...
PR Newswire
27/08/2024

Global Lumbar Disc Replacement Devices Market to Exhibit Significant Growth at a…

Key Takeaways from the Lumbar Disc Replacement Devices Market Report Key Takeaways from the Lumbar Disc Replacement Devices Market Report To read more about the latest highlights related to the lumbar disc replacement devices market, get a snapshot of the key highlights entailed in the Global Lumbar Disc Replacement Devices Market Report Lumbar Disc Replacement Devices Overview Lumbar disc replacement devices are advanced medical implants designed to treat chronic lower back...
PR Newswire
27/08/2024

Oculis Publishes Consolidated Q2 Financial Statements and MD&A

Attachments Oculis Q2 Unaudited Condensed Consolidated Interim Financial StatementsOculis Q2 MD&A
Nasdaq GlobeNewswire
27/08/2024

ONWARD® Medical Schedules Webcast to Provide Half-Year 2024 Business Update

Company to provide more detailed commercial plans for its ARC-EX System The webcast will be held on September 10, 2024, at 2:00PM CET / 08:00AM ET. It will be hosted by CEO Dave Marver who will discuss highlights from 1H 2024 and provide a business update.To join the webcast via Zoom, please register usingthis link.Participants may also join by phone:+32 2 290 9360 (Belgium)+33 1 7095 0350 (France)+49 69 3807 9884 (Germany)+31 20 794 0854 (Netherlands)+41 22 591 0156...
Nasdaq GlobeNewswire
27/08/2024

Novonesis delivers strong half-year results and increases full-year outlook

In the first half of 2024, Novonesis delivered 7% organic sales growth with an adjusted EBITDA margin at 35.3%. Following strong first half-year performance, Novonesis increases its full-year organic sales outlook from 5-7% to 7-8% and increases adjusted EBITDA-margin expectations from 35-36% to 35.5-36.5%.COPENHAGEN, Denmark – August 27, 2024.Novonesis delivers 7% organic sales growth with an adjusted EBITDA margin at 35.3% in the first half of the 2024 financial year, and now expects...
Nasdaq GlobeNewswire
27/08/2024

Interim Report H1 2024

H1 organic pro forma sales growth at 7%, with pro forma adjusted EBITDA margin at 35.3%. Full-year outlook increased. H1 organic pro forma sales growth of 7% and 8% on IFRS reported basis. Q2 organic pro forma sales growth of 10%; Food & Health Biosolutions at 9%; and Planetary Health Biosolutions at 11%. H1 pro forma adjusted EBITDA margin of 35.3%, with 34.0% for Food & Health Biosolutions and 36.3% for Planetary Health Biosolutions. H1 adjusted EBITDA on IFRS reported base...
Nasdaq GlobeNewswire
27/08/2024

Immunohistochemistry (IHC) Market worth $5.2 billion by 2029 driven by Emerging…

Browse in-depth TOC on "Immunohistochemistry Market" Browse in-depth TOC on "Immunohistochemistry Market" 666 - Tables 63 - Figures 489 - Pages F. Hoffmann-La Roche AG: Leading Innovator in Immunohistochemistry F. Hoffmann-La Roche AG ( Switzerland ) stands out as a major player in the global immunohistochemistry (IHC) market. Operating through its Pathology Lab segment within the Diagnostics Division, Roche provides a comprehensive range of IHC products, including the...
PR Newswire
27/08/2024

Bandsaw Machines Market to Reach $3.4 Billion, Globally, by 2033 at 4.3% CAGR…

Prime determinants of growth Prime determinants of growth Increase in construction activities and urbanization globally, rise in industrialization, and surge in popularity of sustainability in industrial sector drive the market growth. However, high initial investment costs restrain the market growth. On the other hand, technological advancements and innovations in bandsaw machines market are anticipated to positively affect the market. Download PDF Sample Copy@...
PR Newswire
27/08/2024

Novonesis increases outlook for full year 2024

Novonesis increases its full-year sales and profitability outlook based on the first half year performance coupled with strong momentum going into the first months of the second half.The 2024 outlook is increased to:• Pro forma organic sales growth of now 7-8% (previously “upper end of 5-7%”)• Pro forma adjusted EBITDA margin of now 35.5-36.5% (previously “35-36%”)Additional information is made available in the Company announcement: Interim Report H1 2024.Attachment ...
Nasdaq GlobeNewswire
27/08/2024

CHiQ ColorLuxe Washing Machine: Laundry with Style and Efficiency

A 13.5-inch ultra-wide LED color touch screen is a feature that distinguishes it from other washing machines. This is not only visually appealing but also serves as an intuitive control center, allowing users to easily navigate through a wide range of wash programs. With just "One Touch to Start," the CHiQ ColorLuxe brings a "Colorful Life" to your laundry routine. A 13.5-inch ultra-wide LED color touch screen is a feature that distinguishes it from other washing machines…
PR Newswire
27/08/2024

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular…

These results are consistent with the four previous randomized clinical trials, the previous LIGHT Trial, and more than ten years of post-marketing safety surveillance data with over 700,000 patient years of product usage. These study results help to substantiate the cardiovascular safety profile of CONTRAVE/MYSIMBA and the ongoing INFORMUS trial. These results are consistent with the four previous randomized clinical trials, the previous LIGHT Trial, and more than ten years of post-marketing...
PR Newswire
27/08/2024

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of…

ORX142 is currently in IND enabling activities for select neurological, neurodegenerative, and psychiatric disorders with excessive daytime sleepiness (EDS) BOSTON and LONDON, Aug.27, 2024(GLOBE NEWSWIRE) --Centessa Pharmaceuticals plc(Nasdaq: CNTA), today announced that preclinical data from a non-human primate (NHP) study of ORX142, a highly potent and selective orexin receptor 2 (OX2R) agonist being developed to address excessive daytime sleepiness (EDS) in select neurological,...
Nasdaq GlobeNewswire
27/08/2024

Surgery Hero wins prestigious NIHR grant to fund long-term study for patients…

This study will provide valuable insights into the potential of digital interventions to enhance recovery and quality of life for patients undergoing major surgeries. The trial's findings, anticipated Q3 2027, will contribute to the growing body of evidence supporting digital prehabilitation and rehabilitation as effective means of improving surgical outcomes. This study will provide valuable insights into the potential of digital interventions to enhance recovery and quality of life for...
PR Newswire
27/08/2024

Alphyn to Present Poster on Zabalafin Hydrogel Clinical Results at European…

The poster, titled "Itch Reduction and Quality of Life Improvement in AD for First Human Use of Zabalafin," is authored by Lynda Spelman, MD1, Stephen Shumack, MD2, Michael Benson, MD3, Bevin Bhoyrul, MD4, Jessie Lee, MD5, Ebrahim AK Abdulla, MD6, Neal Koller7, and Gary Pekoe, PhD7 The poster, titled "Itch Reduction and Quality of Life Improvement in AD for First Human Use of Zabalafin," is authored byLynda Spelman, MD 1,Stephen Shumack, MD 2,Michael Benson, MD 3, Bevin…
PR Newswire
27/08/2024

OKYO Pharma Granted U.S. Patent Covering OK-101's Potential for Treating…

LONDON and NEW YORK, Aug.27, 2024(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today the grant of a key U.S. Patent No. 12,053,501 which issued on...
Nasdaq GlobeNewswire
27/08/2024

ENDO REPORTS SECOND-QUARTER 2024 FINANCIAL RESULTS

The Company continues executing its strategy of becoming a vibrant growth company. With second-quarter results which exceeded internal expectations, the Company is raising 2024 full-year financial expectations and is also providing 2025 financial expectations, which represent a return to growth. The Company continues executing its strategy of becoming a vibrant growth company. With second-quarter results which exceeded internal expectations, the Company is raising 2024 full-year financial...
PR Newswire
27/08/2024

MolecuLight Announces Integration with Intellicure Electronic Health Record…

The benefits of the MolecuLightDX and Intellicure integration include: The benefits of the MolecuLight DXand Intellicure integration include: "Optimizing our customers' clinical workflow is a top priority here at MolecuLight. We are proud to announce the inclusion of our MolecuLight platform in Intellicure EHR," says Anil Amlani, CEO of MolecuLight Inc. "The MolecuLight DXis an extensively validated FDA-cleared Class II device that integrates three essential functions: detection…
PR Newswire
27/08/2024

ENDO ANNOUNCES CEO TRANSITION

Scott Hirsch has been appointed to serve as Endo's Interim CEO in the transition period while the search is ongoing. Scott Hirschhas been appointed to serve as Endo's Interim CEO in the transition period while the search is ongoing. Mr. Hirsch joined the Endo Board of Directors inApril 2024. He has over 20 years of experience in healthcare, investment management, and financial services and was formerly the CEO of Solta Medical, where he led growth of the global business through an...
PR Newswire
27/08/2024

JW Therapeutics Announces NMPA Approval of the Supplemental Biological License…

The sBLA was supported by the clinical results from a single-arm, multi-center, pivotal study on Carteyva® in adult patients with r/r MCL in China. In the study, patients with r/r MCL who had been treated with a CD20-targeting antibody, anthracycline or bendamustine, or BTKis were included. After being treated with lymphodepleting chemotherapy, patients received Carteyva® (100×106 CAR+ T cells). As of August 7th, 2023, a total of 59 patients received Carteyva® infusion. Of 59 efficacy…
PR Newswire
27/08/2024

myTomorrows and Pancreatic Cancer Europe Partner to Support Pancreatic Cancer…

Pancreatic cancer is the fourth leading cause of cancer deaths, with a life expectancy of only 6-12 months at time of diagnosis and a 5-year survival rate of only 10%. The many challenges associated with pancreatic cancer include a lack of awareness about the disease among the public, difficulty in diagnosis, which is late, treatment resistance to chemo and radiation therapy, poor survival rates, and limited treatments. Therefore, it is crucial for patients to be as accurately and thoroughly…
PR Newswire
27/08/2024

OMRON Healthcare to Attend and Sponsor ESC Congress 2024 in London

Prior to the event, the second annual meeting of the AF Screen International Collaboration will take place on Thursday, August 29, 2024. This research group consists of more than 200 well known researchers in AFib from 40 countries, led by a scientific committee of international experts in heart rhythm disorders. During this meeting, participants will have the opportunity to elaborate and agree on future steps to promote discussion and research around AFib detection to reduce stroke risks. OMRON…
PR Newswire
27/08/2024

Oculis Reports Q2 Financial Results and Provides Recent Company Update

Reported positive topline results for the Phase 2b RELIEF trial of OCS-02 (licaminlimab) paving the way for potentially the first precision medicine in Dry Eye Disease (DED)Phase 2 ACUITY trial of OCS-05 in acute optic neuritis (AON) is on track for topline readout in Q4 2024Pre-NDA meeting with U.S. Food and Drug Administration (FDA) completed in August for once daily OCS-01 for the treatment of post-operative inflammation and pain following ocular surgery; Providing a clear path...
Nasdaq GlobeNewswire
27/08/2024

Experts Agree On the Longevity of EMFACE's Non-Invasive Face-Lifting Effects

EMFACE combines Synchronized RF and HIFES™ technologies, patented by BTL. It has become a foundational treatment for many patients seeking aesthetic improvements to their faces and is increasingly popular when used alongside injectable treatments. EMFACE combines Synchronized RF and HIFES ™ technologies, patented by BTL. It has become a foundational treatment for many patients seeking aesthetic improvements to their faces and is increasingly popular when used alongside injectable...
PR Newswire
27/08/2024
Altri  Comunicati